Unmasking risk in low-suspicion thyroid nodules: clinical and sonographic predictors of malignancy in TIRADS 3, a retrospective single-center study
Clinical and Translational Oncology · 2025
DOI: 10.1007/s12094-025-04034-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Dayana Torres-Cuenca und 2 weiteren Autor:innen. Beteiligte Einrichtung: Escuela de Especialidades Médicas, Colegio de Ciencias de la Salud CoCSa' Universidad San Francisco de Quito USFQ, Diego de Robles Street S/N and Pam…. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Thyroid nodules categorized as TIRADS 3 are typically considered low risk for malignancy (estimated < 5%) under the 2017 ACR TI-RADS guidelines. However, the real-world application of these criteria may vary, with many TIRADS 3 nodules undergoing fine-needle aspiration (FNA) despite recommendations for surveillance. This study aimed to identify clinical and ultrasonographic predictors of malignancy in TIRADS 3 nodules to enhance risk stratification. METHODS: This retrospective, single-center study included 200 patients aged 18-65 years with ultrasound-confirmed TIRADS 3 thyroid nodules who underwent FNA between January 2021 and December 2022. Although ACR guidelines recommend biopsy for nodules ≥ 2.5 cm, FNA was also performed in smaller nodules presenting with high-risk features such as capsule bulging or central-peripheral vascularity. Data were collected from anonymized hospital records. Multivariate logistic regression was used to identify independent predictors of malignancy. RESULTS: The malignancy rate was 20%, exceeding the expected threshold for TIRADS 3 nodules. Capsule expansion (OR 18.50, p < 0.001), central-peripheral vascularity (OR 4.99, p = 0.004), and a family history of thyroid cancer (OR 13.08, p = 0.001) were identified as significant predictors. All malignancy diagnoses were based on cytological findings (Bethesda V/VI), with no histopathologic confirmation available. CONCLUSION: Certain TIRADS 3 nodules may possess a higher malignancy risk than traditionally assumed. Incorporating additional ultrasound features and clinical context may improve diagnostic accuracy. Future prospective studies with histopathological confirmation are warranted to validate these predictors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Escuela de Especialidades Médicas, Colegio de Ciencias de la Salud CoCSa' Universidad San Francisco de Quito USFQ, Diego de Robles Street S/N and Pampite, 170901, Quito, Ecuador.
- Hospital Padre Carollo "Un canto para la vida", Av. Rumichaca S33-10, 170146, Quito, Ecuador.
- Facultad de Ciencias Médicas' Unidad de Medicina Traslacional, Universidad Central del Ecuador, Iquique' N14-121 y Sodiro-Itchimbía, 170403, Quito, Ecuador. fabriciogonzaleza@gmail.com.
Zitieren
APA
Torres-Cuenca, D., Ortiz, J. E., & González-Andrade, F. (2025). Unmasking risk in low-suspicion thyroid nodules: clinical and sonographic predictors of malignancy in TIRADS 3, a retrospective single-center study. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04034-5
Vancouver
Torres-Cuenca D, Ortiz JE, González-Andrade F. Unmasking risk in low-suspicion thyroid nodules: clinical and sonographic predictors of malignancy in TIRADS 3, a retrospective single-center study. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04034-5
BibTeX
@article{TorresCuenca2025,
author = {Torres-Cuenca, Dayana and Ortiz, Juan Eduardo and González-Andrade, Fabricio},
title = {Unmasking risk in low-suspicion thyroid nodules: clinical and sonographic predictors of malignancy in TIRADS 3, a retrospective single-center study},
journal = {Clinical and Translational Oncology},
year = {2025},
doi = {10.1007/s12094-025-04034-5}
}
EUVIMED